top of page

【Portfolio】Co-founder and CMO of Basking Bioscience invited as speaker on 2022 World Stroke Congress Singapore

Basking-VVB logo.jpg

The 2022 World Stroke Congress opened in Singapore on 26th Oct.  It was hosted by World Stroke Organization, the only global body solely focused on stroke with over 4200 delegates from 104 countries. It assembled the international stroke community to work together to reduce the burden of stroke by delivering improvements in prevention, treatment and support. It offered the latest on clinical trials, state-of-the-art presentations by renowned clinicians and researchers, and updates on the latest guidelines.

logo-2022.png

On Oct 26, Dr. Shahid Nimjee, the Co-founder and CMO of Basking Bioscience, was invited to make speech on Advances in Neurosurgical ICH Approaches in the Onsite Stroke and Live Streamed Session

 

Hightlights of Dr. Shahid Nimjee

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  • PhD from Duke University

  • Co-Director of Stroke Center

  • Lawrence J. Mervis, MD, Teacher of the Year Award, Department of Neurosurgery

  • Named to the Castle Connolly list of “Regional Top Doctors,” 2021

  • The Ohio State University College of Medicine Leadership and Chair Award

  • Speaker at TEDxOSU

  • Best Scientific Paper Award at the cerebrovascular section meeting of the American Association of Neurological Surgeons and Congress of Neurological Surgeons

 

About Basking

 

Basking is developing the first in class agent (BB-031) targeting von Willebrand Factor (VWF) along with a direct acting reversal agent (BB-025) to immediately the pharmacological effect of BB-031 in the event of bleeding. BB-031 is an RNA aptamer optimized for rapid onset of action and short duration of effect. Basking will initiate a Phase 2 trial in acute ischemic stroke in late 2022 and is exploring further application in pulmonary embolism in preclinical studies. The technology is based on two decades of translational research on RNA aptamers as therapeutic agents for cardiovascular diseases.

www.baskingbiosciences.com

 

About World Stroke Congress

 

worldstrokecongress.org

Shahid Nimjee, MD, PhD.jpg

Dr. Shahid Nimjee

Co-founder and CMO, Basking Bioscience

Assoc. Professor, Neurosurgery Ohio State University

Use this space to introduce yourself and share your professional history.

This website is for informational purposes only and does not constitute an offer to sell, a solicitation to buy, or a recommendation for any security; nor does it constitute an offer to provide investment advisory or other services by Viva Ventures Biotech Fund or any of our affiliates. Nothing contained on the website constitutes investment advice or offers any opinion with respect to the suitability of any security, and the views expressed on this website should not be taken as advice to buy, sell, or hold any security or as an endorsement of any security or company. In preparing the information contained in this website, Viva Ventures Biotech has not taken into account the investment needs, objectives, and financial circumstances of any particular investor, and investments and companies referenced may not be suitable for all investors. Any views expressed on this website by Viva Ventures biotech were prepared based upon information, believed to be reliable, available to it at the time such views were written. Viva Ventures Biotech makes no guarantees as to their accuracy or completeness. All information is subject to change and may quickly become unreliable for various reasons, including changes in market conditions or economic circumstances. By accessing this website, the reader agrees that he/she not copy, reproduce, republish, upload, post, transmit, alter, or distribute in any way material from this website in any manner inconsistent with the purposes for which it is offered without the prior written consent of Viva Ventures Biotech.

bottom of page